

BIOGEN IDEC INC.

Form 4

April 10, 2008

FORM 4
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Hasnain Faheem

(Last) (First) (Middle)

14 CAMBRIDGE CENTER

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
BIOGEN IDEC INC. [BIIB]

3. Date of Earliest Transaction
(Month/Day/Year)
04/08/2008

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
X Officer (give title below) ____ Other (specify
below)

EVP, Oncology/Rheumatology SBU

6. Individual or Joint/Group Filing(Check
Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/08/2008		S ⁽¹⁾	100 D	\$ 38,441.2214 63.71 ⁽²⁾	D	
Common Stock	04/08/2008		S ⁽¹⁾	200 D	\$ 38,241.2214 63.79	D	
Common Stock	04/08/2008		S ⁽¹⁾	200 D	\$ 38,041.2214 63.89	D	
Common Stock	04/08/2008		S ⁽¹⁾	100 D	\$ 37,941.2214 63.93	D	
Common Stock	04/08/2008		S ⁽¹⁾	300 D	\$ 37,641.2214 64.18	D	

Edgar Filing: BIOGEN IDEC INC. - Form 4

Common Stock	04/08/2008	<u>S⁽¹⁾</u>	500	D	\$ 64.32	37,141.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	400	D	\$ 64.38	36,741.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	2	D	\$ 64.39	36,739.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	200	D	\$ 64.4	36,539.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	998	D	\$ 64.42	35,541.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	800	D	\$ 64.44	34,741.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	25	D	\$ 64.48	34,716.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	300	D	\$ 64.51	34,416.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	100	D	\$ 64.54	34,316.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	100	D	\$ 64.58	34,216.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	100	D	\$ 64.61	34,116.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	300	D	\$ 64.63	33,816.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	100	D	\$ 64.64	33,716.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	100	D	\$ 64.67	33,616.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	300	D	\$ 64.72	33,316.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	400	D	\$ 64.79	32,916.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	400	D	\$ 64.82	32,516.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	100	D	\$ 64.92	32,416.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	200	D	\$ 64.93	32,216.2214	D
Common Stock	04/08/2008	<u>S⁽¹⁾</u>	100	D	\$ 64.94	32,116.2214	D

Edgar Filing: BIOGEN IDEC INC. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Hasnain Faheem
14 CAMBRIDGE CENTER
CAMBRIDGE, MA 02142

EVP, Oncology/Rheumatology SBU

Signatures

Robert A. Licht, Attorney in Fact for Faheem
Hasnain

04/10/2008

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

(2) Includes 464,5978 shares acquired under the Biogen Idec Inc. employee stock purchase plan on 3/31/2008.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.